| Oct 3 |
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
|
| Sep 4 |
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
|
| Aug 7 |
OptimizeRx Q2 2024 Earnings Preview
|
| Aug 1 |
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 25 |
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
|
| Jul 23 |
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
|
| Jul 15 |
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
|
| Jun 20 |
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
|
| May 15 |
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
|
| May 14 |
OptimizeRx Non-GAAP EPS of -$0.11 misses by $0.01, revenue of $19.7M beats by $1.57M
|
